Payment overview · 2025
General Payments
$1,333.22
60 reported records · 13 companies
Healthcare provider profile · identity verified
Edward E. Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · FLUSHING, NY · NPI 1144394966
Verified facts
What the public records show
CMS Open Payments records show Edward E. Lee, M.D. received $1,333.22 in general payments during 2025 across 60 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia, Linzess, Veltassa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Aranesp by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $259.89 | 19.5% | 16 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $191.13 | 14.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.95 | 13.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $140.41 | 10.5% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.07 | 7.5% | 5 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.74 | 7.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.58 | 5.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.97 | 5.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.58 | 4.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $53.22 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.72 | 3.6% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $40.39 | 3.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.57 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,333.22 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $259.89 | 16 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $191.13 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $173.95 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $114.59 | 5 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $85.38 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $80.54 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.58 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.97 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.95 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 283 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 241 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
283 | 50 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
268 | 43 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
52 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
241 | 44 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
199 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
175 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1116 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 923 | 143 |
| Vascepa | Icosapent Ethyl | 780 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 678 | 114 |
| Losartan Potassium | Losartan Potassium | 662 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 82 |
| Metformin Hcl | Metformin Hcl | 432 | 71 |
| Mirtazapine | Mirtazapine | 387 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 387 | 68 |
| Doxazosin Mesylate | Doxazosin Mesylate | 370 | 63 |
| Repaglinide | Repaglinide | 360 | 51 |
| Creon | Lipase/Protease/Amylase | 283 | 50 |
| Omeprazole | Omeprazole | 279 | 54 |
| Simvastatin | Simvastatin | 277 | 46 |
| Tradjenta | Linagliptin | 277 | 38 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 268 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 38 |
| Farxiga | Dapagliflozin Propanediol | 241 | 44 |
| Donepezil Hcl | Donepezil Hcl | 215 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 36 |
| Diclofenac Epolamine | Diclofenac Epolamine | 207 | 28 |
| Trulicity | Dulaglutide | 199 | 30 |
| Veltassa | Patiromer Calcium Sorbitex | 175 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 173 | 30 |
| Gabapentin | Gabapentin | 160 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 150 | 34 |
| Lidocaine | Lidocaine | 143 | 18 |
| Finasteride | Finasteride | 134 | 24 |
| Metformin Hcl Er | Metformin Hcl | 133 | 23 |
| Calcium Acetate | Calcium Acetate | 127 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 126 | 18 |
| Nifedipine Er | Nifedipine | 121 | 17 |
| Febuxostat | Febuxostat | 118 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 114 | 27 |
| Clonidine Hcl | Clonidine Hcl | 107 | 31 |
| Carvedilol | Carvedilol | 104 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 17 |
| Januvia | Sitagliptin Phosphate | 97 | 13 |
| Folic Acid | Folic Acid | 90 | 16 |
| Livalo | Pitavastatin Calcium | 87 | 13 |
| Jardiance | Empagliflozin | 76 | 14 |
| Bydureon Bcise | Exenatide Microspheres | 74 | suppressed |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 70 | 18 |
| Alendronate Sodium | Alendronate Sodium | 66 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 62 | suppressed |
| Pregabalin | Pregabalin | 62 | suppressed |
| Allopurinol | Allopurinol | 60 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 60 | suppressed |
| Meloxicam | Meloxicam | 56 | 23 |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 55 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 54 | 36 |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 52 | 28 |
| Prolia | Denosumab | 52 | 32 |
| Ozempic | Semaglutide | 51 | suppressed |
| Famotidine | Famotidine | 50 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Restasis | Cyclosporine | 49 | suppressed |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Lisinopril | Lisinopril | 46 | suppressed |
| Prednisone | Prednisone | 46 | suppressed |
| Cilostazol | Cilostazol | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | suppressed |
| Azithromycin | Azithromycin | 41 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Dexilant | Dexlansoprazole | 39 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Furosemide | Furosemide | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| True Comfort Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,333.22 · 60 records | Bayer Healthcare Pharmaceuticals Inc. | CREON, FARXIGA, Fabhalta, GEMTESA, JASCAYD, JYNARQUE, Kerendia, LINZESS, MOUNJARO, OTEZLA, RAYALDEE, REPATHA, VOYXACT, Vanrafia, Veltassa, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error